Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3027 | Saline oral/nasal rinse Wiki | 0.71 |
| drug878 | Continuation of anti-TNF treatment Wiki | 0.71 |
| drug1074 | Discontinuation of anti-TNF treatment Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D041881 | Cholecystitis, Acute NIH | 0.71 |
| D002764 | Cholecystitis NIH | 0.71 |
| D042101 | Acalculous Cholecystitis NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002583 | Colitis HPO | 0.25 |
| HP:0100279 | Ulcerative colitis HPO | 0.25 |
Navigate: Correlations HPO
There are 2 clinical trials
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF treatment after a relapse
Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 2 years of randomized treatment
Measure: Proportion of patients in sustained clinical remission Time: 2 yearsDescription: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 4 years of randomized treatment
Measure: Proportion of patients in sustained clinical remission Time: 4 yearsDescription: Relapse time
Measure: Time from randomization to relapse Time: 2 yearsDescription: Relapse time
Measure: Time from randomization to relapse Time: 4 yearsDescription: Remission, but no need to restart anti-tnf therapy
Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy Time: 2 yearsDescription: Remission, but no need to restart anti-tnf therapy
Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy Time: 4 yearsDescription: Remission after relapse
Measure: Proportion of relapse patients achieving remission after anti-TNF restart Time: 2 yearsDescription: Remission after relapse
Measure: Proportion of relapse patients achieving remission after anti-TNF restart Time: 4 yearsDescription: Adverse events
Measure: Adverse events and serious adverse events frequency and severity Time: 2 yearsDescription: Adverse events
Measure: Adverse events and serious adverse events frequency and severity Time: 4 yearsThe ChoCO (Cholecystitis under COVID-19 pandemic) STUDY PROTOCOL Gangrenous cholecystitis is the most common complication of acute cholecystitis, affecting around 15% (range 2-30%) of patients and it occurs as a result of ischemia with necrosis of the gallbladder wall. Preliminary data showed that COVID-19 patients have a high risk to present necrotic cholecystitis. Our aim is to investigate risk factors related to develop necrotic cholecystitis in COVID-19 negative and positive patients carrying out a multicentric prospective observational study.
Description: Our hypothesis is that COVID-19 patients should not treated conservatively (antibiotics only/ percutaneous drainage of gallbladder for the high risk of progressing to necrotic and then perforated cholecystitis. It was reported that COVID-19 disease predisposes to both venous and arterial thromboembolism, explained by excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. In particular, critically ill patients with SARS-CoV-2 showed a high risk to present a thromboembolic events.
Measure: Risk factors for necrotic cholecystitis in COVID-19 patients Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports